CTA 313
Alternative Names: CTA-313Latest Information Update: 11 Nov 2025
At a glance
- Originator Nanjing Bioheng Biotech
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Lupus nephritis; Systemic lupus erythematosus
- Preclinical Neurological disorders
Most Recent Events
- 11 Nov 2025 Preclinical trials in Autoimmune disorders in China (Parenteral) (Nanjing Bioheng Biotech pipeline, November 2025)
- 11 Nov 2025 Preclinical trials in Neurological disorders in China (Parenteral) (Nanjing Bioheng Biotech pipeline, November 2025)
- 11 Nov 2025 Nanjing Bioheng Biotech plans a phase I trial for Autoimmune disorders in 2026 (Nanjing Bioheng Biotech pipeline, November 2025)